Johnson & Johnson scraps Alzheimer's trials on safety concerns

May 18 (Reuters) - Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.